- Home
- / Celldex Therapeutics
Celldex Therapeutics
Stock Price
$46.4
2023-03-01
Market Capitalization
$2.2 B
2023-03-01
Revenue
$2.4 M
FY, 2022
Celldex Therapeutics Summary
Company summary
- Overview
- Celldex Therapeutics (formerly known as Avant Immunotherapeutics) is developing targeted therapeutics to address devastating diseases. It offers Immuno-oncology, Therapeutic antibodies, immune system modulators, inflammatory diseases, and other services.
- Type
- Public
- Status
- Active
- Founded
- 1983
- HQ
- Hampton, NJ, US | view all locations
- Website
- https://celldex.com/
- Cybersecurity rating
- ESG rating
Key people
Sarah Boylan Cavanaugh, Senior Vice President, Corporate Affairs & Administration
Tibor Keler, Founder, Executive Vice President & Chief Scientific Officer
Thomas Davis, CMO, SVP Clinical Development
Operating MetricsView all
Patents Issued
300
FY, 2016
LocationsView all
4 locations detected
Hampton, NJ HQ
United States
53 Frontage Rd #220
Fall River, MA
United States
151 martine street
Needham, MA
United States
160 Gould St #202
New Haven, CT
United States
300 George St #530
Celldex Therapeutics Financials
Summary financials
- Revenue (FY, 2022)
- $2.4M
- Gross profit (FY, 2022)
- $2.3M
- Net income (FY, 2022)
- ($113.0M)
- Cash (FY, 2022)
- $29.4M
- EBIT (FY, 2022)
- ($115.2M)
- Enterprise value
- $2.2B
News
Blogs
Footer menu
Products
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension